Dynavax Technologies Operating Income 2010-2022 | DVAX

Dynavax Technologies operating income from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Dynavax Technologies Annual Operating Income
(Millions of US $)
2021 $134
2020 $-68
2019 $-135
2018 $-153
2017 $-96
2016 $-111
2015 $-105
2014 $-91
2013 $-66
2012 $-68
2011 $-48
2010 $-48
2009 $-15
Dynavax Technologies Quarterly Operating Income
(Millions of US $)
2022-03-31 $31
2021-12-31 $81
2021-09-30 $16
2021-06-30 $9
2021-03-31 $29
2020-12-31 $-12
2020-09-30 $-14
2020-06-30 $-23
2020-03-31 $-19
2019-12-31 $-27
2019-09-30 $-31
2019-06-30 $-39
2019-03-31 $-38
2018-12-31 $-38
2018-09-30 $-39
2018-06-30 $-38
2018-03-31 $-38
2017-12-31 $-28
2017-09-30 $-22
2017-06-30 $-20
2017-03-31 $-25
2016-12-31 $-19
2016-09-30 $-35
2016-06-30 $-29
2016-03-31 $-27
2015-12-31 $-27
2015-09-30 $-28
2015-06-30 $-23
2015-03-31 $-26
2014-12-31 $-22
2014-09-30 $-30
2014-06-30 $-25
2014-03-31 $-14
2013-12-31 $-13
2013-09-30 $-16
2013-06-30 $-17
2013-03-31 $-21
2012-12-31 $-20
2012-09-30 $-17
2012-06-30 $-15
2012-03-31 $-16
2011-12-31 $-5
2011-09-30 $-15
2011-06-30 $-10
2011-03-31 $-18
2010-12-31 $-16
2010-09-30 $-7
2010-06-30 $-16
2010-03-31 $-9
2009-12-31 $-12
2009-09-30 $-11
2009-06-30 $3
2009-03-31 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.425B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00